Institute for Collaboration on Health Intervention and Policy, University of Connecticut.
Department of Medicine, Mercer University Medical School.
Behav Med. 2022 Jul-Sep;48(3):190-197. doi: 10.1080/08964289.2020.1809336. Epub 2020 Oct 14.
This study tested the hypothesis that the co-occurrence of alcohol use and depressive symptoms predicts HIV suppression and antiretroviral therapy (ART) adherence among people living with HIV. Baseline cross-sectional results showed a significant interaction between depressive symptoms and alcohol use in predicting HIV suppression; individuals who drank more alcohol and had higher depressive symptoms demonstrated poorer HIV suppression relative to those who had fewer depressive symptoms. In a one-year longitudinal analysis of ART adherence, alcohol use and depressive symptoms measured in daily text-message assessments demonstrated that neither alcohol use nor depressive symptoms alone predicted ART adherence. However, the intersection of alcohol use on days when experiencing depressive symptoms did significantly predict ART non-adherence, for both moderate and heavy alcohol drinkers. Findings suggest that the co-occurrence of alcohol use and depressive symptoms is a robust predictor of poor HIV treatment outcomes.
本研究检验了这样一个假设,即饮酒和抑郁症状同时出现预测了 HIV 感染者的 HIV 抑制和抗逆转录病毒治疗(ART)的依从性。基线横断面研究结果显示,抑郁症状和饮酒之间存在显著的交互作用,可预测 HIV 抑制情况;与抑郁症状较少的个体相比,饮酒较多且抑郁症状较高的个体 HIV 抑制效果较差。在一项为期一年的 ART 依从性纵向分析中,每日短信评估中测量的饮酒和抑郁症状表明,单独的饮酒或抑郁症状均不能预测 ART 依从性。然而,在经历抑郁症状的日子里,饮酒的交叉出现确实显著预测了中度和重度饮酒者的 ART 不依从,这一发现表明,饮酒和抑郁症状同时出现是 HIV 治疗效果不佳的一个强有力的预测因素。